Next Article in Journal
Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment
Next Article in Special Issue
Molecular Mechanisms and Pathways as Targets for Cancer Prevention and Progression with Dietary Compounds
Previous Article in Journal
iTRAQ-Based Quantitative Proteomic Analysis Reveals Cold Responsive Proteins Involved in Leaf Senescence in Upland Cotton (Gossypium hirsutum L.)
Previous Article in Special Issue
Dietary Phenethyl Isothiocyanate Protects Mice from Colitis Associated Colon Cancer
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(9), 1980;

The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan

Renal Physiopathology Laboratory, Depterment of Nephrology, Instituto Nacional de Cardiología “Ignacio Chávez”, Mexico City 14080, Mexico
Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados-IPN, Mexico City 07360, Mexico
Histopathology Laboratory, Research Subdivision, School of Medicine, Universidad Panamericana, Donatello 43, Mexico City 03910, Mexico
Author to whom correspondence should be addressed.
Received: 20 July 2017 / Revised: 24 August 2017 / Accepted: 13 September 2017 / Published: 16 September 2017
(This article belongs to the Special Issue Nutraceuticals in Human Health and Disease)
Full-Text   |   PDF [4848 KB, uploaded 16 September 2017]   |  


Recent studies suggest that allicin may play a role in chronic kidney disease (CKD), reducing hypertension and oxidative stress and improving renal dysfunction. In the present study, CKD was induced by 5/6 nephrectomy and the animals were divided into four treatment groups as follows: control (C), CKD, CKD+allicin (40 mg/kg pathway oral) (CKDA), and CKD+Losartan (20 mg/kg) (CKDL). After CKD induction, the rats developed hypertension from week 3 to the end of the study. This was associated with increased creatinine and blood urea nitrogen (BUN) levels in serum, increased albuminuria, increased urinary excretion of N-acetyl-β-d-glucosaminidase (NAG), increased nephrin expression, and incrased histological alterations in the cortex. The levels of angiotensin receptors and endothelial nitric oxide synthase (eNOS) were decreased in the renal cortex from the CKD group. Otherwise, lipid and protein oxidation were higher in the CKD group than in the control group. A disturbance was observed in the expression levels of the nuclear factor erythroid 2-related factor 2/Kelch ECH associating protein 1 system (Nrf2/keap1) and the antioxidant enzymes catalase, superoxide dismutase, and heme oxygenase-1. Allicin or losartan treatments relieved renal dysfunction, hypertension, and oxidative stress. In addition, both treatments showed the same efficacy on the expression of angiotensin receptors, the nephrin, Nrf2/keap1 pathway, and eNOS. Further in silico analyses suggest that allicin and losartan could have a common mechanism involving interaction with AT1 receptors. Allicin showed antihypertensive, antioxidant, and nephroprotective effects. The beneficial effects showed by allicin are similar, or even better, than those of losartan. In fact, the effect of allicin on blood pressure and renal function is comparable to reductions seen with losartan, a prescription drug commonly used as a first-line therapy. View Full-Text
Keywords: allicin; hypertension; chronic kidney disease; oxidative stress; losartan allicin; hypertension; chronic kidney disease; oxidative stress; losartan

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

García Trejo, E.M.Á.; Arellano Buendía, A.S.; Sánchez Reyes, O.; García Arroyo, F.E.; Arguello García, R.; Loredo Mendoza, M.L.; Tapia, E.; Sánchez Lozada, L.G.; Osorio Alonso, H. The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan. Int. J. Mol. Sci. 2017, 18, 1980.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top